Thomas discusses the importance of measuring omega-3 levels before supplementing and the dilemma of prescribing EPA versus DHA in high-risk patients. He also challenges the hypothesis that triglyceride and HDL levels alone determine cardiovascular risk, emphasizing the need for clinical trial data to support such claims.
